MTOR and pancreatic neuroendocrine tumor: Pancreatic ductal adenocarcinoma cells, leukemic cells, and pancreatic neuroendocrine tumor cells all displayed comparable effects, and in both subtypes of pancreatic cancer, concurrent treatment with mTOR inhibitors enhanced the antiproliferative effects of NAMPT inhibition (Zucal et al., 2015; Mpilla et al., 2019).